Cosmo Pharmaceuticals N.V.
Cosmo Pharmaceuticals N.V. (CMOPF) Stock Overview
Explore Cosmo Pharmaceuticals N.V.’s financial performance, market position, analyst ratings, and future outlook.
Key Financials
Key Financials
Market Cap
2.4B
P/E Ratio
37.14
EPS (TTM)
$4.24
ROE
0.12%
CMOPF Stock Analysis & Investment Overview
Our comprehensive AI-powered analysis of Cosmo Pharmaceuticals N.V. (CMOPF) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B+, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.
The current technical analysis reveals key indicators including an RSI of 53.16, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $111.14.
Key financial metrics showcase the company's fundamental strength, including a P/E ratio of 37.14 and a market capitalization of 2.4B. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.